Cargando…
The Impact of Medical and Health Fiscal Expenditures on Pharmaceutical Industry Stock Index in China
This paper investigates the relationship between fiscal expenditure on health care (FE) and the pharmaceutical industry stock index (SP) by using full-sample and sub-sample rolling-window bootstrap causality tests. It can be observed that there is both a positive and negative relationship between FE...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9517157/ https://www.ncbi.nlm.nih.gov/pubmed/36142003 http://dx.doi.org/10.3390/ijerph191811730 |
_version_ | 1784798869942435840 |
---|---|
author | Su, Chiwei Liu, Yiru Liu, Chang Tao, Ran |
author_facet | Su, Chiwei Liu, Yiru Liu, Chang Tao, Ran |
author_sort | Su, Chiwei |
collection | PubMed |
description | This paper investigates the relationship between fiscal expenditure on health care (FE) and the pharmaceutical industry stock index (SP) by using full-sample and sub-sample rolling-window bootstrap causality tests. It can be observed that there is both a positive and negative relationship between FE and SP. FE will promote the rise of the pharmaceutical stock market, which proves the Keynesian theory, while the result that FE negatively affects SP supports the classical theory. In turn, SP positively impacts FE, which indicates that the development of the pharmaceutical industry and the increase in medical and health expenditures can promote each other. In addition, the negative influence of SP on FE suggests that the impact of the pharmaceutical index on fiscal expenditure needs to be judged in conjunction with other events and market conditions. In complex economic conditions, investors can rationally consider the industry situation of the pharmaceutical market and benefit by optimising their investment portfolios. The government can regulate and guide the pharmaceutical industry by adjusting the fiscal expenditure on health care, thereby promoting the sustainable and stable development of the financial market. |
format | Online Article Text |
id | pubmed-9517157 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95171572022-09-29 The Impact of Medical and Health Fiscal Expenditures on Pharmaceutical Industry Stock Index in China Su, Chiwei Liu, Yiru Liu, Chang Tao, Ran Int J Environ Res Public Health Article This paper investigates the relationship between fiscal expenditure on health care (FE) and the pharmaceutical industry stock index (SP) by using full-sample and sub-sample rolling-window bootstrap causality tests. It can be observed that there is both a positive and negative relationship between FE and SP. FE will promote the rise of the pharmaceutical stock market, which proves the Keynesian theory, while the result that FE negatively affects SP supports the classical theory. In turn, SP positively impacts FE, which indicates that the development of the pharmaceutical industry and the increase in medical and health expenditures can promote each other. In addition, the negative influence of SP on FE suggests that the impact of the pharmaceutical index on fiscal expenditure needs to be judged in conjunction with other events and market conditions. In complex economic conditions, investors can rationally consider the industry situation of the pharmaceutical market and benefit by optimising their investment portfolios. The government can regulate and guide the pharmaceutical industry by adjusting the fiscal expenditure on health care, thereby promoting the sustainable and stable development of the financial market. MDPI 2022-09-17 /pmc/articles/PMC9517157/ /pubmed/36142003 http://dx.doi.org/10.3390/ijerph191811730 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Su, Chiwei Liu, Yiru Liu, Chang Tao, Ran The Impact of Medical and Health Fiscal Expenditures on Pharmaceutical Industry Stock Index in China |
title | The Impact of Medical and Health Fiscal Expenditures on Pharmaceutical Industry Stock Index in China |
title_full | The Impact of Medical and Health Fiscal Expenditures on Pharmaceutical Industry Stock Index in China |
title_fullStr | The Impact of Medical and Health Fiscal Expenditures on Pharmaceutical Industry Stock Index in China |
title_full_unstemmed | The Impact of Medical and Health Fiscal Expenditures on Pharmaceutical Industry Stock Index in China |
title_short | The Impact of Medical and Health Fiscal Expenditures on Pharmaceutical Industry Stock Index in China |
title_sort | impact of medical and health fiscal expenditures on pharmaceutical industry stock index in china |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9517157/ https://www.ncbi.nlm.nih.gov/pubmed/36142003 http://dx.doi.org/10.3390/ijerph191811730 |
work_keys_str_mv | AT suchiwei theimpactofmedicalandhealthfiscalexpendituresonpharmaceuticalindustrystockindexinchina AT liuyiru theimpactofmedicalandhealthfiscalexpendituresonpharmaceuticalindustrystockindexinchina AT liuchang theimpactofmedicalandhealthfiscalexpendituresonpharmaceuticalindustrystockindexinchina AT taoran theimpactofmedicalandhealthfiscalexpendituresonpharmaceuticalindustrystockindexinchina AT suchiwei impactofmedicalandhealthfiscalexpendituresonpharmaceuticalindustrystockindexinchina AT liuyiru impactofmedicalandhealthfiscalexpendituresonpharmaceuticalindustrystockindexinchina AT liuchang impactofmedicalandhealthfiscalexpendituresonpharmaceuticalindustrystockindexinchina AT taoran impactofmedicalandhealthfiscalexpendituresonpharmaceuticalindustrystockindexinchina |